Evaluation of a computer-based intervention to enhance metabolic monitoring in psychiatry inpatients treated with second-generation antipsychotics

Journal of Clinical Pharmacy and Therapeutics

Volumn 37, Issue 6, 2012, Pages 668-673

  DelMonte, M T ^a   Bostwick, J R ^b   Bess, J D ^b   Dalack, G W ^b  

^a UNIVERSITY OF NORTH CAROLINA HOSPITALS   (United States)

^b UNIVERSITY OF MICHIGAN HEALTH SYSTEM   (United States)

Author keywords

chronic mental illness; computerized physician order entry system; metabolic monitoring; metabolic syndrome; second generation antipsychotics

Indexed keywords

ARIPIPRAZOLE; CLOZAPINE; GLUCOSE; NEUROLEPTIC AGENT; OLANZAPINE; PALIPERIDONE; QUETIAPINE; RISPERIDONE; ZIPRASIDONE;

ADULT; ARTICLE; COMORBIDITY; COMPUTERIZED PROVIDER ORDER ENTRY; CONTROLLED STUDY; DEMOGRAPHY; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; MENTAL PATIENT; PATIENT LABORATORY METABOLIC MONITORING; PATIENT MONITORING;

ADULT; ANTIPSYCHOTIC AGENTS; BLOOD GLUCOSE; DATABASES, FACTUAL; DRUG MONITORING; FEMALE; GUIDELINE ADHERENCE; HOSPITALS, UNIVERSITY; HUMANS; INPATIENTS; LENGTH OF STAY; LIPIDS; MALE; MEDICAL ORDER ENTRY SYSTEMS; MENTAL DISORDERS; MIDDLE AGED; PRACTICE GUIDELINES AS TOPIC; PSYCHIATRIC DEPARTMENT, HOSPITAL; RETROSPECTIVE STUDIES;

EID: 84868377208     PISSN: 02694727     EISSN: 13652710     Source Type: Journal    
DOI: 10.1111/j.1365-2710.2012.01369.x     Document Type: Article

References (15)

1. Sernyak MJ,. Implementation of monitoring and management guidelines for second-generation antipsychotics. J Clin Psychiatry, 2007; 68 (Suppl. 4): 14-18.
2. American Diabetes Association, American Psychiatric Association, American Association of Clinical Endocrinologists, North American Association for the Study of Obesity. Consensus development conference on antipsychotic drugs and obesity and diabetes. J Clin Psychiatry, 2004; 65: 267-272.
3. Straker D, Correll C, Kramer-Ginsberg E, et al. Cost-effective screening for the metabolic syndrome in patients treated with second-generation antipsychotic medications. Am J Psychiatry, 2005; 162: 1217-1220.
4. Reeves R, Kaldany H, Lieberman H, Vyas R,. Creation of a metabolic monitoring program for second-generation (atypical) antipsychotics. J Correct Health Care, 2009; 15: 292-301.
5. Newcomer JW,. Antipsychotic medications: metabolic and cardiovascular risk. J Clin Psychiatry, 2007; 68 (Suppl. 4): 8-12.
6. Chwastiak LA, Rosenheck RA, Kazis LE,. Association of psychiatric illness and obesity, physical inactivity, and smoking among a national sample of veterans. Psychosomatics, 2011; 52: 230-236.
7. Ganguli R, Strassnig M,. Prevention of metabolic syndrome in serious mental illness. Psychiatr Clin North Am, 2011; 34: 109-125.
8. Haupt DW, Rosenblatt LC, Kim E, Baker RA, Whitehead R, Newcomer JW,. Prevalence and predictors of lipid and glucose monitoring in commercially insured patients treated with second-generation antipsychotic agents. Am J Psychiatry, 2009; 166: 345-353.
9. Morrato EH, Newcomer JW, Allen RR, Valuck RJ,. Prevalence of baseline serum glucose and lipid testing in users of second-generation antipsychotic drugs: a retrospective, population-based study of Medicaid claims data. J Clin Psychiatry, 2008; 69: 316-322.
10. Morrato EH, Newcomer JW, Kamat S, Baser O, Harnett J, Cuffel B,. Metabolic screening after the American Diabetes Association's consensus statement on antipsychotic drugs and diabetes. Diabetes Care, 2009; 32: 1037-1042.
11. Morrato EH, Druss B, Hartung DM, Valuck RJ, Allen R, Campagna E, Newcomer JW,. Metabolic testing rates in 3 state Medicaid programs after FDA warnings and ADA/APA recommendations for second-generation antipsychotic drugs. Arch Gen Psychiatry, 2010; 67: 17-24.
12. Schneiderhan ME, Batscha CL, Rosen C,. Assessment of a point-of-care metabolic risk screening program in outpatients receiving antipsychotic agents. Pharmacotherapy, 2009; 29: 975-987.
13. Feldstein AC, Smith DH, Perrin N, et al. Improved therapeutic monitoring with several interventions: a randomized trial. Arch Intern Med, 2006; 166: 1848-1854.
14. Were MC, Shen C, Tierney WM, et al. Evaluation of computer-generated reminders to improve CD4 laboratory monitoring in sub-Saharan Africa: a prospective comparative study. J Am Med Inform Assoc, 2011; 18: 150-155.
15. Lo HG, Matheny ME, Seger DL, Bates DW, Gandhi TK,. Impact of non-interruptive medication laboratory monitoring alerts in ambulatory care. J Am Med Inform Assoc, 2009; 16: 66-71.